Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 6/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23473311 | 0.83 | LMNA (0.40) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| Isocaffiene SCHEMBL515995 | 0.80 | LMNA (0.57) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL23974894 | 0.79 | LMNA (0.38) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL23974900 | 0.79 | ADORA3 (0.52) | ADORA2BCYP3A4 | |
| SCHEMBL28973366 | 0.76 | TNF (0.43) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL21534087 | 0.75 | ADORA2B (0.43) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL19013753 | 0.74 | SMN1; SMN2 (0.50) | LMNACYP1A2CYP3A4 | |
| SCHEMBL516446 | 0.73 | ADORA2A (0.74) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL15086862 | 0.73 | LMNA (0.40) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL13111707 | 0.73 | PDE1A (0.49) | PDE4AADORA2APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083743-A1 | NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF | WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY (CN) | 2026-03-26 | — | — | US | disclosed |
| US-20220288084-A1 | NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF | WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY (CN) | 2022-09-15 | — | — | US | disclosed |
| CN-109912598-B | Nucleoside derivative for preventing and treating inflammatory reaction and application thereof | 四川大学华西医院 | 2022-09-13 | — | — | CN | disclosed |
| EP-3950689-A1 | NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF | West China Hospital of Sichuan University (CN) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020192665-A1 | NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF | 四川大学华西医院 | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083743-A1 | NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF | SLC5A1, PC, LDHA | PDE4A 2742/4885ADORA2A 314/4885PDE4B 2990/4885 |
| US-20220288084-A1 | NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF | PNP, HMGB3, ADAR | PDE4A 348/4885ADORA2A 29/4885PDE4B 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.